2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P5183
    Hm1a
    		Activator
    Hm1a is a disulfide-rich spider-venom peptide, and a NaV1.1 activator. Hm1a restores the function of inhibitory interneurons in Dravet syndrome (DS) mouse model.
    Hm1a
  • HY-101437A
    Ralfinamide mesylate
    Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain.
    Ralfinamide mesylate
  • HY-B1798R
    Tocainide (Standard)
    		Inhibitor
    Tocainide (Standard) is the analytical standard of Tocainide. This product is intended for research and analytical applications. Tocainide hydrochloride is an orally activesodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus.
    Tocainide (Standard)
  • HY-123493
    P552-02 mesylate
    		Inhibitor
    P552-02 (552-02) mesylate is a sodium channel blocker that is potentially used for the treatment of cystic fibrosis, exhibiting biological activity that enhances mucociliary clearance in the lungs while minimizing the risk of hyperkalaemia.
    P552-02 mesylate
  • HY-B0824R
    Bifenthrin (Standard)
    		Activator
    Bifenthrin (Standard) is the analytical standard of Bifenthrin. This product is intended for research and analytical applications. Bifenthrin is a synthetic pyrethroid insecticide. Bifenthrin prolongs the opening time of Nav1.8 sodium channels, leading to membrane depolarization and conductance block in the insect nervous system, thereby disrupting neural function. Bifenthrin was effective in inhibiting A. gambiae (LD50=0.15 ng/mg) and C. quinquefasciatus (LD50=0.16 ng/mg). Bifenthrin has good lethality against susceptible and resistant mosquitoes and is very effective in inhibiting blood sucking and can be developed as a mosquito-removal netting material.
    Bifenthrin (Standard)
  • HY-171778
    QLS-81
    		Inhibitor
    QLS-81 is a Nav1.7 channel inhibitor (IC50: 1.5 μM). QLS-81 has significant analgesic activity and can relieve neuropathic and inflammatory pain. QLS-81 exerts frequency-dependent inhibitory effects by inhibiting the inactivated state of Nav1.7 channels. QLS-81 can be used in the study of chronic pain.
    QLS-81
  • HY-175289
    hERG-IN-3
    		Inhibitor
    hERG-IN-3 is an orally active hERG blocker with an IC50 of 44.5 nM. hERG-IN-3 exhibits a Ki for β2-adrenergic receptor of 14 nM. hERG-IN-3 exhibits the skeletal muscle Nav1.4 and sodium channel-blocking activities (IC50 = 4.4 μM, 3-fold increasement than hNav1.5). hERG-IN-3 displays a potent antimyotonic activity in an animal model. hERG-IN-3 can be used for the study of Myotonia Congenita.
    hERG-IN-3
  • HY-135495
    AM-0466
    		Inhibitor
    AM-0466 is a sodium channel inhibitor with nanomolar levels of NaV1.7 inhibitory activity. AM-0466 exhibits potent pharmacodynamic activity in a NaV1.7-dependent histamine-induced itch model. AM-0466 also showed significant analgesic effects in capsaicin-induced pain models. After optimizing its pharmacokinetic properties, AM-0466 was advanced into in vivo targeting and efficacy models for testing.
    AM-0466
  • HY-W415121R
    Bupivacaine hydrochloride monohydrate (Standard)
    		Inhibitor
    Bupivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Bupivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate (Standard)
  • HY-B0161CR
    (R)-Duloxetine (Standard)
    		Inhibitor
    (R)-Duloxetine (Standard) is the analytical standard of (R)-Duloxetine. This product is intended for research and analytical applications. (R)-Duloxetine is a form of Duloxetine (HY-B0161) that causes tonic and usage-dependent impairment of neuronal Na+ channels. (R)-Duloxetine can be used in pain research.
    (R)-Duloxetine (Standard)
  • HY-P4898
    Anthopleurin-A
    		Modulator
    Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone.
    Anthopleurin-A
  • HY-121535
    Levosemotiadil
    		Inhibitor
    Levosemotiadil, an S-isomer of semotiadil, exhibits stronger binding affinity to human serum albumin (HSA) compared to its R-isomer counterpart. This study utilized high-performance frontal analysis (HPFA) to demonstrate that levosemotiadil binds approximately three times more strongly to HSA than semotiadil. The binding parameters were evaluated using Scatchard analysis, revealing specific interactions with the diazepam binding site on HSA. The presence of diazepam decreased the binding affinity of both enantiomers, while warfarin did not alter their binding characteristics. These findings highlight levosemotiadil's potential as a Ca- and Na-channel blocker with significant binding preferences for HSA, crucial for understanding its pharmacokinetics and therapeutic effects.
    Levosemotiadil
  • HY-Z8176
    (Z)-Flunarizine
    		Inhibitor
    (Z)-Flunarizine is the (Z)-isomer of Flunarizine (HY-B0358). Flunarizine is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
    (Z)-Flunarizine
  • HY-162757
    Anticonvulsant agent 5
    		Modulator
    Anticonvulsant agent 5 (Compound 5c) exhibits high affinity for GABAA receptors and NaV1.3 receptors. Anticonvulsant agent 5 shows anticonvulsant efficacy in mice psychomotor epilepsy test with an ED50 of 107 mg/kg. Anticonvulsant agent 5 exhibits neuroprotective activity against Kainic acid (HY-N2309) with an IC50 of 113 μM. Anticonvulsant agent 5 is blood-brain barrier (BBB) penetrable.
    Anticonvulsant agent 5
  • HY-111245
    AZD-1305
    		Inhibitor
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research.
    AZD-1305
  • HY-174845
    Nav1.8-IN-20
    		Inhibitor
    Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC50 value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain.
    Nav1.8-IN-20
  • HY-160663
    Nav1.7 blocker 1
    Nav1.7 blocker 1 (example 41) is a Na+ channel (Nav) blocker with an IC50 value of 0.037 μM. Nav1.7 blocker 1 can be used for the study of pain, including neuropathic pain, postoperative pain, inflammatory pain, and so on.
    Nav1.7 blocker 1
  • HY-P5942
    Pterinotoxin-2
    		Inhibitor
    Pterinotoxin-2 is a sodium channel inhibitor peptide toxin.
    Pterinotoxin-2
  • HY-B0703S
    Eslicarbazepine acetate-d4
    		Inhibitor
    Eslicarbazepine acetate-d4 is deuterated labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
    Eslicarbazepine acetate-d4
  • HY-P5784
    δ-Buthitoxin-Hj1a
    		Agonist
    δ-Buthitoxin-Hj1a, a scorpion-venom peptide, is a potent NaV1.1 agonist with an EC50 of 17nM. δ-Buthitoxin-Hj1a can be used for the Dravet syndrome (DS) research.
    δ-Buthitoxin-Hj1a
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.